Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 16/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118238 | 0.90 | POLB (0.39) | SLC40A1DHODHKMT2AMAPK14 | |
| SCHEMBL4123415 | 0.88 | MAPK14 (0.34) | SLC40A1DHODHMAPK14 | |
| SCHEMBL4138889 | 0.88 | NPC1 (0.34) | SLC40A1DHODH | |
| SCHEMBL4137742 | 0.87 | GSK3B (0.38) | DHODHKMT2AMAPK14 | |
| SCHEMBL4125428 | 0.87 | MAPT (0.38) | SLC40A1ATM | |
| SCHEMBL4130943 | 0.86 | MAPT (0.38) | — | |
| SCHEMBL4118036 | 0.82 | DHODH (0.36) | SLC40A1DHODHKMT2A | |
| SCHEMBL4135549 | 0.80 | DHODH (0.36) | DHODHATMKMT2A | |
| SCHEMBL3655560 | 0.79 | DHODH (0.34) | DHODHKMT2AMAPK14 | |
| SCHEMBL4139211 | 0.79 | LIPG (0.36) | SLC40A1DHODHATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC40A1 2890/4885DHODH 1560/4885ATM 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.